Clinical Trial Update: A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

This is a Phase 2 dose-escalation study evaluating RT234 in subjects with pulmonary arterial hypertension. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• RT234

Snippet

Sponsor: Respira Therapeutics, Inc. | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED